Diaxonhit Share Price Euronext Paris
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 254M 284M 234M 212M 397M 26.97B 404M 2.82B 1.12B 14.13B 1.07B 1.04B 44.55B | P/E 2026 * |
22.3x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 222M 248M 205M 186M 347M 23.57B 353M 2.46B 976M 12.35B 932M 912M 38.93B | EV / Sales 2026 * |
1.26x | EV / Sales 2027 * | - |
| Free-Float |
96.48% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 12/06/2023 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 09/10/2023 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 31/12/2018 | |
Michel Picot
BRD | Director/Board Member | 73 | 26/06/2019 |
| Director/Board Member | 69 | 14/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | -.--% | - | - | 284M | |
| +2.41% | +0.29% | +39.41% | +72.14% | 64.69B | |
| -0.15% | +7.50% | +11.42% | +71.27% | 54.78B | |
| +0.57% | +4.60% | +7.71% | +90.93% | 53.49B | |
| +0.37% | +4.67% | +26.68% | +49.64% | 45.98B | |
| -1.21% | +2.32% | +21.50% | +118.33% | 42.94B | |
| -0.37% | +5.07% | +243.23% | +789.58% | 40.08B | |
| +0.05% | +0.21% | +18.06% | +48.50% | 33.52B | |
| +1.19% | -4.98% | +26.31% | -0.76% | 23.97B | |
| -0.38% | +5.68% | +38.39% | +28.35% | 23.67B | |
| Average | +0.06% | +2.41% | +48.08% | +140.89% | 42.57B | |
| Weighted average by Cap. | +0.39% | +2.73% | +46.02% | +142.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 197M 162M 147M 276M 18.7B 280M 1.96B 774M 9.8B 739M 724M 30.89B | - |
| Net income | 11.6M 12.99M 10.72M 9.71M 18.17M 1.23B 18.47M 129M 51.05M 646M 48.75M 47.71M 2.04B | - |
| Net Debt | -32M -35.83M -29.56M -26.79M -50.12M -3.4B -50.95M -356M -141M -1.78B -134M -132M -5.62B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
